Literature DB >> 20495865

Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint.

Nicholas J Robert1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495865     DOI: 10.1007/s10549-010-0919-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  1 in total

1.  Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials.

Authors:  Cunfu Li; Aizhai Xiang; Xianzhi Chen; Kai Yin; Jinsong Lu; Wenjin Yin
Journal:  Onco Targets Ther       Date:  2017-06-27       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.